Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gilgamesh Pharmaceuticals

Explore full profile

Provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders

New York City, United StatesFounded 2019Biotech & Life Sciences
Valuation $100–250M Last recorded · 2026
Revenue $50–100M Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Gilgamesh Pharmaceuticals and the history behind them.

About Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical-stage biotech startup that operates in the mental health treatment market. The company's primary focus is to revolutionize the treatment of mental illnesses by shifting from symptom management to creating rapid-acting and durable therapies that target the root causes of the diseases.

The company's business model is centered around designing new chemical entities (NCEs), which are essentially new drugs that have not been approved by the FDA yet. These NCEs are created to act through proven mechanisms and are optimized for safety, efficacy, and patient accessibility. This means that Gilgamesh is committed to creating drugs that are not only effective and safe but also easily accessible to patients.

Gilgamesh collaborates with leading research institutions in the biotech field, leveraging their expertise and resources to drive innovation. This collaborative approach allows the company to stay at the forefront of biotech innovation, which is crucial in the highly competitive and rapidly evolving biotech industry.

The company generates revenue through the development and commercialization of its NCEs. Once an NCE is approved by the FDA, Gilgamesh can sell the drug to healthcare providers and patients. The company may also generate income through partnerships with other biotech companies or research institutions.

In summary, Gilgamesh Pharmaceuticals is a clinical-stage biotech company that aims to revolutionize mental health treatment by developing new, safe, and accessible drugs that target the root causes of mental illnesses.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
New York City, United States
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Series A12 investors entered at this stage

  • Prime Movers Lab
  • Palo Alto Investors
  • Gron Ventures
  • Route 66 Ventures
  • Noetic Fund
  • JLS Fund
  • Ayuh Ventures
  • Alumni Ventures
  • Negev Capital
  • Satori Capital
  • Palo Santo Venture Fund
  • Satori Neuro

Series B and later6 investors entered at this stage

  • Alumni Ventures
  • Satori Capital
  • Columbia University
  • Negev Capital
  • Ayuh Ventures
  • Palo Santo Venture Fund
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States93.5%
🇨🇭 Switzerland3.2%
🇹🇷 Turkey3.2%
3 countries shown
Web traffic by country
6.2K monthly visits
across markets
🇺🇸 United States91.9%
🇮🇳 India8.1%
Top 2 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Gilgamesh Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gilgamesh Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.